ClinicalTrials.gg
Status unknownNCT02129114Updated Jul 8, 2014

Study to Evaluate the Safety and Efficacy of Dural Repair Patch in Neurosurgical Repairs

An interventional study of ReDura Onlay and DuraGen in Neurosurgical Repairs, sponsored by Medprin Regenerative Medical Technologies Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Medprin Regenerative Medical Technologies Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2014), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

  1. Most of dural defects may lead to subcutaneous effusion and Cerebral Spinal Fluid (CSF) leakage, which may result in infection; besides, direct adhesion of brain tissues with sub-scalp tissues also increase the risk of epilepsy, in severe cases, dural defect is considered a life-threatening condition. So, it's important to repair the dura mater for restoring its full integrity .
  2. Dural Repair Patch(ReDura Onlay) manufactured by Guangzhou Medprin Regenerative Medical Technologies Co., Ltd. As a product made of clinical absorbable polymer materials by using bionic technology, Dural Repair Patch has highly bionic 3-dimensional structure which is proved to facilitate migration and growth of regenerative cells, as well as to accelerate the growth and repairing of regenerative meninges. While the material is degraded gradually and absorbed by the body, regenerative meningeal tissue is gradually formed, achieving true reconstruction of the dura mater.
  3. To evaluate the safety and effectiveness of Dural Repair Patch in neurosurgical repairs of dural defects.
Read the detailed description
  1. Dura mater is an important structural cell layer on the surface of brain serving as an important barrier for brain protection. Dural defects could be caused by a vast variety of factors, including trauma, tumor invasion, increased volume of the intra-cranial contents, certain congenital diseases, surgical procedures and etc. Most of dural defects may lead to subcutaneous effusion and CSF leakage, which may result in infection; besides, direct adhesion of brain tissues with sub-scalp tissues also increase the risk of epilepsy, in severe cases, dural defect is considered a life-threatening condition. Repairing of dura mater to restore its full integrity is proved to reduce the incidences of its complications, such as CSF leakage, epilepsy and etc. In particular, the outcomes of neurosurgeries are largely dependent of the post-operative integrity of dura mater.
  2. most of the currently available products require surgical dural suturing, which elongate the duration of operation; nevertheless, some surgical site are unsuitable for suturing. The currently marketed non-suture dural substitutes and mainly made of a single material with a single-layered structure, which are significantly different from the natural structure of extracellular matrix, poorly mimicking the microstructure of dural mater; hence, the structures and surface properties of such products do not meet the requirements for local cellular regeneration post dural repairs, resulting in poor repair outcomes. Besides, the increased contractility of these products after water absorption also impose a certain extent of risk in practical application, since dural repairing surgeries are mainly conducted on the defective site of soft cerebral tissues.
  3. As a product prepared by using bionic technology, Dural Repair Patch manufactured by Guangzhou Medprin Regenerative Medical Technologies Co., Ltd. is able to mimic porous fiber biomimetic structure that facilitate the cellular growth on the stent. Through effective control over the bionic technology parameters, the diameter, aperture and porosity of the fiber are almost identical to the in vivo tissue structure, so as to improve the cellular adhesion and growth on the sten. Increased strength, suitable ductility and improved hydrophilicity all contribute to the excellent flexibility and adhesiveness of the finished product able to adhesive closely to the autologous tissues, meeting the clinical requirements. Being made of absorbable polymer materials widely accepted in clinical product, the product has a highly bionic 3-dimensional structure which is proved to facilitate migration and growth of regenerative cells, as well as to accelerate the growth and repairing of regenerative meninges. While the material is degraded gradually and absorbed by the body, regenerative meningeal tissue is gradually formed, achieving true reconstruction of the dura mater.
  4. Design and methods

4.1 Subjects who meet the inclusion criteria are randomized in accordance with the admission time; routine blood test, liver and kidney function test, as well as cellular and humoral immunity test are conducted prior to the surgery.

4.2 Location, characteristics and size of the defects,as well as the conditions of surgical incision are all observed intra-operatively.

4.3 Dura mater membrane repairing surgeries are conducted by closely attaching either an appropriately-sized test product or reference product to the defected part of dura mater membrane, before the incision in the skull is closed by using a conventional approach.

4.4 The subjects'conditions are reviewed on Day 1, 3, 5, 7 and 10 post operations, respectively.

4.5 Lumbar puncture is conducted on Day 10±2 post operation based on the subject's conditions, in order to measure the intracranial pressure and test for cerebrospinal fluid leakage; routine blood, liver and kidney function, as well as cellular and humoral immunity are re-tested on Day 10±2 post operation and the values obtained are compared with the pre-operative baseline measurements and recorded, so as to evaluate the clinical significance; On Day 10±2 post operation, cerebrospinal fluid leakage or subcutaneous effusion are examined by CT scan and clinical examinations, so as to assess the relationship of such events to the test/reference product.

4.6 For subjects who received a re-operation in the same location or a second neurosurgery, the conditions of test product or reference product in the repairing site is observed, e.g. examine (combined with histological test) product adhesion with cerebral tissues and etc.

4.7 The subjects are asked to attend a return visit or a telephone follow-up session on Day 90±10 and 180±20 post operation.

02

Conditions studied

  • Neurosurgical Repairs
03

In context

Lead sponsor

Medprin Regenerative Medical Technologies Co., Ltd. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. male or female aged 18-65 years;
  2. whose expected survival is not less than 12 months
  3. Patients with dura mater defects which occurred in a variety of neurosurgeries (including traumatic brain injury, brain tumors, cerebrovascular disease, congenital neurological diseases, intra-spinal diseases and etc.) and required surgical repairing.
  4. All the enrolled subjects should not present obvious pre-operative inflammation symptoms,
  5. Written informed consents were obtained from all of the patients and/or their guardians.

Exclusion criteria

Exclusion Criteria:

  1. Patient who present severe visceral (heart, liver, kidney, circulation system or etc.) diseases.
  2. Patient with unstable vital signs.
  3. Pregnant or lactating women.
  4. Patient who have a past history of serious allergy
  5. Patient who have a past history of severe immunodeficiency disease.
  6. Other undesirable conditions set by investigators.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    ReDura Onlay

    The Dural Repair Patch manufactured by Guangzhou Medprin Regenerative Medical Technologies Co., Ltd.

    Device: ReDura Onlay

  • Active comparator
    DuraGen

    Dural Graft Matrix manufactured by Integra LifeSciences (U.S.) Corporation.

    Device: DuraGen

Interventions

  • DeviceReDura Onlay

    Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.

  • DeviceDuraGen

    Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.

06

What researchers measure

Primary outcomes

  1. Rate of successful prevention of CSF leakage

    on Day 10±2 post operation, occurrence of CSF leakage is checked on both CT and clinical examination

    Time frame: Day 10±2 post operation

Secondary outcomes

  1. Healing of scalp incision

    the healing of scalp incision is reviewed on Day 3, Day 5, Day7, Day 10, Month 3 and Month 6, respectively.

    Time frame: 6 month

07

Study locations

1 of 1 sites recruiting
  • Zhujiang Hospital of Southern Medical University
    GuangZhou, Guangdong 510000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Dec 2014 and a completion of May 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2014
First posted
May 2, 2014
Start
Apr 2014
Primary completionEst.
Dec 2014
CompletionEst.
May 2015
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02129114
Responsible party
Sponsor
First posted
May 2, 2014
Start date
Apr 2014
Primary completion
Dec 2014 (estimated)
Completion
May 2015 (estimated)
Last update
Jul 8, 2014

Study contacts

Tian Quan, Manager
Contact
tianquan@medprin.com
020-32296115
Ke Yi Quan, professor
principal investigator · Southern Medical University, China

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion